Comparing Antipsychotic Treatments for Schizophrenia: A Health State Approach.
Saved in:
| Title: | Comparing Antipsychotic Treatments for Schizophrenia: A Health State Approach. |
|---|---|
| Authors: | Lin, Lewei, Rosenheck, Robert, Sugar, Catherine, Zbrozek, Arthur |
| Source: | Psychiatric Quarterly. Mar2015, Vol. 86 Issue 1, p107-121. 15p. 5 Charts, 1 Graph. |
| Subjects: | Antipsychotic agents, Schizophrenia treatment, Randomized controlled trials, Quality of life, Drug side effects, Mental illness |
| Abstract: | The overall impact of first and second generation antipsychotics on quality of life and symptoms of people with schizophrenia remains controversial. We applied health state modeling to data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia study, a randomized trial of antipsychotic medications, and evaluated the likelihood of patients moving to more favorable health states over time. We applied K-means clustering to the data to create discrete groupings of patients with symptom and side effect characteristics that were then validated using quality of life measures. We compared cluster distributions across medications at baseline and 6 months after randomization. 1,049 patients were included in the initial cluster analysis. Five health states were identified: (1) low symptoms and low side effects (LS + LSE) (2) low symptoms and obesity (LS + Ob) (3) high symptoms and low side effects (HS + LSE) (4) high symptoms with depression and akathisia (HS + Dp + Ak) and (5) moderate symptoms and high side effects (MS + HSE). Six-month outcomes among patients randomly assigned to perphenazine, olanzapine, risperidone and quetiapine were compared. At baseline, almost 20 % of patients were in the worst health state (HS + Dp + Ak), with greater decreases at 6 months in this health state for perphenazine (9.2 % decrease) and olanzapine (11.1 %) groups compared to risperidone (4.7 %) and quetiapine (6.7 %). This study demonstrated that health state analysis can provide insight into the overall clinical state of patients beyond the mere comparison of average scores and largely confirmed original CATIE findings. [ABSTRACT FROM AUTHOR] |
| Copyright of Psychiatric Quarterly is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 101555147 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Comparing Antipsychotic Treatments for Schizophrenia: A Health State Approach. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Lin%2C+Lewei%22">Lin, Lewei</searchLink><br /><searchLink fieldCode="AR" term="%22Rosenheck%2C+Robert%22">Rosenheck, Robert</searchLink><br /><searchLink fieldCode="AR" term="%22Sugar%2C+Catherine%22">Sugar, Catherine</searchLink><br /><searchLink fieldCode="AR" term="%22Zbrozek%2C+Arthur%22">Zbrozek, Arthur</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Psychiatric+Quarterly%22">Psychiatric Quarterly</searchLink>. Mar2015, Vol. 86 Issue 1, p107-121. 15p. 5 Charts, 1 Graph. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Antipsychotic+agents%22">Antipsychotic agents</searchLink><br /><searchLink fieldCode="DE" term="%22Schizophrenia+treatment%22">Schizophrenia treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Randomized+controlled+trials%22">Randomized controlled trials</searchLink><br /><searchLink fieldCode="DE" term="%22Quality+of+life%22">Quality of life</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+side+effects%22">Drug side effects</searchLink><br /><searchLink fieldCode="DE" term="%22Mental+illness%22">Mental illness</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: The overall impact of first and second generation antipsychotics on quality of life and symptoms of people with schizophrenia remains controversial. We applied health state modeling to data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia study, a randomized trial of antipsychotic medications, and evaluated the likelihood of patients moving to more favorable health states over time. We applied K-means clustering to the data to create discrete groupings of patients with symptom and side effect characteristics that were then validated using quality of life measures. We compared cluster distributions across medications at baseline and 6 months after randomization. 1,049 patients were included in the initial cluster analysis. Five health states were identified: (1) low symptoms and low side effects (LS + LSE) (2) low symptoms and obesity (LS + Ob) (3) high symptoms and low side effects (HS + LSE) (4) high symptoms with depression and akathisia (HS + Dp + Ak) and (5) moderate symptoms and high side effects (MS + HSE). Six-month outcomes among patients randomly assigned to perphenazine, olanzapine, risperidone and quetiapine were compared. At baseline, almost 20 % of patients were in the worst health state (HS + Dp + Ak), with greater decreases at 6 months in this health state for perphenazine (9.2 % decrease) and olanzapine (11.1 %) groups compared to risperidone (4.7 %) and quetiapine (6.7 %). This study demonstrated that health state analysis can provide insight into the overall clinical state of patients beyond the mere comparison of average scores and largely confirmed original CATIE findings. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Psychiatric Quarterly is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=101555147 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s11126-014-9326-2 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 15 StartPage: 107 Subjects: – SubjectFull: Antipsychotic agents Type: general – SubjectFull: Schizophrenia treatment Type: general – SubjectFull: Randomized controlled trials Type: general – SubjectFull: Quality of life Type: general – SubjectFull: Drug side effects Type: general – SubjectFull: Mental illness Type: general Titles: – TitleFull: Comparing Antipsychotic Treatments for Schizophrenia: A Health State Approach. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Lin, Lewei – PersonEntity: Name: NameFull: Rosenheck, Robert – PersonEntity: Name: NameFull: Sugar, Catherine – PersonEntity: Name: NameFull: Zbrozek, Arthur IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 03 Text: Mar2015 Type: published Y: 2015 Identifiers: – Type: issn-print Value: 00332720 Numbering: – Type: volume Value: 86 – Type: issue Value: 1 Titles: – TitleFull: Psychiatric Quarterly Type: main |
| ResultId | 1 |
